Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership
This article was originally published in PharmAsia News
Executive Summary
Joint research effort by three New York-based academic research organizations seeks to expedite translation of basic biomedical research into innovative therapies. Initial focus is on small molecules, but the plan is to branch out eventually into monoclonal antibodies and molecular imaging agents, as well.
You may also be interested in...
Pharma Continues Its March To Academia, as Sanofi, UCB Strike Deals
In two very different collaborations, Sanofi teams up with Weill Cornell professor to screen for TB drug candidates, while UCB initiates its first project under a strategic research alliance with Harvard.
Coronavirus Update: Gilead's Veklury Gets Full FDA Approval, Roche Partners With Atea
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
US COVID-19 Vaccine Adcomm: First Take-Aways
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Need a specific report? 1000+ reports available
Buy Reports